News

Scientists grow specialized motor neurons to aid in ALS research

Scientists have developed a way to grow motor neurons, the highly specialized nerve cells that are lost in amyotrophic lateral sclerosis (ALS), opening the door to new research avenues for treatment discovery. The new approach directs rare adult brain progenitor cells to become corticospinal-like neurons, a type of nerve…

ALS survey shows patients value even modest treatment gains

For many people with amyotrophic lateral sclerosis (ALS), even a slight slowing of disease progression is considered clinically meaningful, according to a new study based on a survey of hundreds of patients. “These results highlight the need for clinical trial designs that are capable of detecting small but meaningful…

Redesigned Target ALS website improves accessibility for patients

Target ALS has announced the launch of its redesigned website, which improves accessibility and highlights its research initiatives to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS). The new digital platform offers an improved experience for the ALS community, facilitating access to more information about…

Computer model shows why the timing of ALS treatment is critical

Scientists have developed a new computer-based model that mimics the spinal cord’s neural networks to predict how nerve cells degenerate in amyotrophic lateral sclerosis (ALS). Using this simulation, researchers discovered that targeting a specific group of “coordinator” cells, known as V1 interneurons, could prevent motor neuron death.

Dewpoint’s new drug candidate targets ALS protein clumps

Dewpoint Therapeutics has selected a novel small molecule designed to prevent the formation of abnormal TDP-43 protein clumps that drive nerve cell death in amyotrophic lateral sclerosis (ALS) and other related conditions. The candidate is specifically designed to target condensates, or membrane-less structures that concentrate specific molecules to…